Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

31 października 2026 zaktualizowane przez: National Cancer Institute (NCI)

A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer

This phase II trial tests how well enzomenib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow or spread despite androgen deprivation therapy (castration-resistant). The growth and survival of prostate tumor cells often depends on testosterone. Androgen deprivation therapy blocks the use of testosterone by the tumor cells. Although most tumors respond to androgen deprivation therapy at first, nearly all eventually progress to a castration-resistant state. Enzomenib, a menin inhibitor, targets and blocks menin, a protein that plays a role in the survival and growth of tumor cells.

Przegląd badań

Szczegółowy opis

PRIMARY OBJECTIVE:

I. To assess the efficacy of DSP-5336 (enzomenib) as measured by fluorodeoxyglucose (FDG)-positron emission tomography (PET) metabolic response rate, in patients with advanced treatment-refractory prostate cancer.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

II. To determine the activity of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

III To assess the pharmacodynamics of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

IV. To assess the pharmacokinetics of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

EXPLORATORY OBJECTIVES:

I. To identify molecular subpopulations associated with response. II. To evaluate circulating tumor deoxyribonucleic acid (DNA) (ctDNA) as a predictor for response.

III. To evaluate differential metabolic responses between prostate-specific membrane antigen (PSMA)-positive and PSMA-negative lesions.

OUTLINE:

Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/computed tomography (CT), PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study.

After completion of study treatment, patients are followed up at 30 days then every 3 months for up to 12 months.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

24

Faza

  • Faza 2

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Męski

Opis

Inclusion Criteria:

  • At the time of informed consent, be ≥ 18 years of age. Because no dosing or adverse event data are currently available on the use of DSP-5336 (enzomenib) in patients < 18 years of age, and because prostate cancer is an adult malignancy, pediatric patients are not part of the target disease population, therefore children are excluded from this study

  • Histologically confirmed prostate adenocarcinoma

  • Metastatic disease documented by conventional imaging, including cross-sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. Advanced imaging, including PSMA PET/CT or FDG PET/CT, may be used as supportive documentation but is not sufficient as the sole evidence of metastatic disease for eligibility

  • Patients with treated, stable brain metastases are eligible if neurologically stable for ≥ 4 weeks and not requiring corticosteroids for central nervous system (CNS) disease for at least 7 days prior to registration. Routine screening for asymptomatic CNS metastases is not required

  • Participants with documented progressive metastatic castration-resistant prostate cancer (mCRPC), as assessed by the treating physician based on at least 1 of the following criteria:

    • Prostate specific antigen (PSA) progression may be used for study eligibility, either alone or with radiographic progression. PSA progression is defined as a rise in PSA that is both ≥ 25% and ≥ 2.0 ng/mL above the lowest PSA value since the start of the most recent systemic therapy, or above the pre-treatment baseline PSA if there was no PSA decline. The rise must be confirmed by a second PSA value obtained at least 3 weeks/21 days later. The reference PSA must be ≥ 1.0 ng/mL. Radiographic disease progression in soft tissue based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
    • Radiographic disease progression in bone, defined as appearance of 2 or more new bone lesions on bone scan
  • Participants must have received prior systemic therapy for advanced or metastatic prostate cancer, including both of the following:

    • At least one androgen receptor pathway inhibitor, such as abiraterone, enzalutamide, apalutamide, or darolutamide. Androgen receptor pathway inhibitor (ARPI) exposure in the metastatic castration-sensitive, non-metastatic castration-resistant, or metastatic castration-resistant setting may satisfy this requirement and
    • At least one prior taxane chemotherapy regimen, such as docetaxel or cabazitaxel, and/or PSMA-targeted radioligand therapy. At least one therapy satisfying this second requirement must have been administered in the metastatic castration-resistant setting
  • Prior poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy, immunotherapy, radium-223, or other standard therapies are permitted but are not required to satisfy eligibility

  • Therapy administered solely in the localized, neoadjuvant, adjuvant, or locally advanced setting does not count toward the required prior therapy history. Docetaxel administered solely in the metastatic castration-sensitive setting does not satisfy the required mCRPC therapy criterion

  • Prior orchiectomy or medical castration, with castrate levels of serum testosterone defined as testosterone ≤ 50 ng/dL documented prior to initiation of study treatment. Participants receiving medical castration with a gonadotrophin releasing hormone (GnRH) agonist or antagonist must continue androgen deprivation therapy throughout the treatment phase

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)

  • Absolute neutrophil count ≥ 1,000/mcL

  • Platelets ≥ 75,000/mcL

  • Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN), except in patients with Gilbert syndrome, who may enroll if total bilirubin is ≤ 3 x institutional ULN and direct bilirubin is ≤ 1.5 x institutional ULN

  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotranferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN

  • Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m^2

  • Participants must be willing to undergo baseline and on-treatment tumor biopsies and must have a lesion considered safely accessible for biopsy by the procedural team. Biopsies may be obtained from soft tissue or bone lesions, although soft tissue biopsy is preferred when feasible

  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

  • Patients must have disease evaluable for the primary FDG PET metabolic response endpoint, defined as at least one FDG-avid lesion evaluable on baseline FDG PET/CT. The baseline FDG PET/CT must be performed during screening, and the presence of at least one FDG-avid, evaluable lesion must be confirmed prior to registration. RECIST 1.1 measurable disease is not required for eligibility. Patients with RECIST 1.1 measurable disease will be evaluable for RECIST-based secondary response assessments

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better. Participants must have Fridericia's formula-corrected QT interval (QTcF) ≤ 480 msec based on screening electrocardiogram

  • The effects of DSP-5336 (enzomenib) on the developing human fetus are unknown. For this reason and because menin inhibitors agents are known to be teratogenic, men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of DSP-5336 (enzomenib) administration. Participants should not donate sperm for the duration of study participation, and 6 months after completion of the last dose of study drug

Exclusion Criteria:

  • Prior treatment with a menin inhibitor (any investigational compound targeting the menin-MLL complex)
  • Untreated, symptomatic, active, or progressive CNS metastases
  • Inability or unwillingness to undergo FDG and PSMA PET/CT imaging, including inability to lie flat for > 30 minutes. Patients with uncontrolled diabetes mellitus are not eligible if fasting blood glucose cannot be controlled to ≤ 200 mg/dL, or to the institutional threshold required for interpretable FDG PET/CT imaging, despite appropriate medical management
  • Known hypersensitivity to DSP-5336 (enzomenib) or any of its excipients
  • Patients who have received systemic anticancer therapy, including oral anticancer therapy, chemotherapy, radioligand therapy, immunotherapy, targeted therapy, investigational anticancer agents, or other investigational agents, within 5 half-lives or 14 days, whichever is shorter, prior to initiation of study treatment. Longer washout may be required when clinically appropriate based on unresolved toxicity or prolonged expected pharmacodynamic effect. Patients who have received external beam radiation therapy within 2 weeks prior to initiation of study treatment are not eligible. Routine concomitant medications are permitted unless otherwise prohibited by the protocol. Ongoing androgen deprivation therapy with a GnRH agonist or antagonist is permitted
  • Concomitant use of medications known to cause QT prolongation that cannot be safely discontinued or substituted prior to initiation of study treatment
  • Patients with uncontrolled intercurrent illness or any other significant condition(s), including active infection requiring intravenous systemic therapy, that would make participation in this protocol unreasonably hazardous

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treatment (androgen deprivation therapy, enzomenib)

Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/CT, PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study.

Undergo blood sample collection

Inne nazwy:
  • Pobieranie próbek biologicznych
  • Zebrano próbki biologiczne
  • Kolekcja próbek

Undergo bone scan

Inne nazwy:
  • Scyntygrafia kości

Undergo tissue biopsy

Inne nazwy:
  • Bx
  • TYP_BIOPSY
  • Biopsja

Given FDG

Inne nazwy:
  • 18FDG
  • FDG
  • fludeoksyglukoza F 18
  • Fludeoksyglukoza (18F)
  • Fludeoksyglukoza F18
  • Fluor-18 2-Fluoro-2-deoksy-D-glukoza
  • Fluorodeoksyglukoza F18

Undergo FDG PET/CT

Inne nazwy:
  • FDG
  • FDG-PET
  • Obrazowanie FDG-PET

Given usual androgen deprivation therapy

Inne nazwy:
  • ADT
  • Terapia deprywacji androgenów
  • Terapia antyandrogenowa
  • Leczenie antyandrogenowe
  • Terapia deprywacji hormonalnej
  • Terapia deprywacji androgenów (ADT)

Undergo CT, FDG PET/CT, and PSMA PET/CT

Inne nazwy:
  • Tomografia komputerowa
  • KOT
  • Skanowanie CAT
  • Tomografia komputerowa osiowa
  • Komputerowa tomografia osiowa
  • tomografia
  • Komputerowa tomografia osiowa (zabieg)
  • Tomografia komputerowa (CT).
  • Diagnostyczny skan CAT
  • Diagnostyczny typ usługi skanowania CAT

Given PO

Inne nazwy:
  • DSP 5336
  • DSP-5336
  • DSP5336
  • Menin Inhibitor DSP-5336
  • Menin-MLL Interaction Inhibitor DSP-5336

Undergo PSMA PET/CT

Inne nazwy:
  • PSMA PET
  • Specyficzny dla prostaty antygen błonowy PET
  • Pozytonowa tomografia emisyjna PSMA

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Fluorodeoxyglucose (FDG) positron emission tomography metabolic response rate
Ramy czasowe: Up to 12 months

Will be defined as the proportion of patients achieving a ≥ 30% reduction from baseline in total FDG uptake (standardized uptake value [SUVtotal]) across all FDG-avid lesions. The response rate will be estimated along with its exact 95% confidence interval (CI).

Up to 12 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Incidence of adverse events
Ramy czasowe: Up to 30 days after last dose of study treatment

Will be graded according to current Cancer Therapy Evaluation Program-required Common Terminology Criteria for Adverse Events version. Will be summarized by type, grade, seriousness, attribution, and relationship to study treatment.

Up to 30 days after last dose of study treatment
Overall response rate
Ramy czasowe: Up to 12 months

Will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 and Prostate Cancer Working Group 3 (PCWG3). Will be reported with exact 95% CI where applicable. Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
Radiographic progression-free survival (PFS)
Ramy czasowe: Up to 12 months

Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
Prostate specific antigen (PSA)-PFS
Ramy czasowe: Up to 12 months

Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
Duration of response (DOR)
Ramy czasowe: From first documented response to radiographic or clinical progression, or death, assessed up to 12 months

Kaplan-Meier estimates of median DOR and 95% CIs will be provided.

From first documented response to radiographic or clinical progression, or death, assessed up to 12 months
Time to PSA progression
Ramy czasowe: From treatment initiation to confirmed PSA progression, will be assessed up to 12 months

Progression will be assessed using PCWG3. Will be summarized using Kaplan-Meier methods.

From treatment initiation to confirmed PSA progression, will be assessed up to 12 months
Overall survival (OS)
Ramy czasowe: From treatment initiation to death from any cause, assessed up to 12 months

Will be summarized using Kaplan-Meier estimates, including median OS and 95% CIs.

From treatment initiation to death from any cause, assessed up to 12 months
Tumor response signatures
Ramy czasowe: Up to 12 months

Bulk ribonucleic sequencing will be evaluated for transcriptome changes. Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
DSP-5336 (enzomenib) pharmacokinetics (PK)
Ramy czasowe: Up to 12 months

PK parameters will be summarized descriptively, and exploratory exposure-safety and exposure-response relationships may be evaluated.

Up to 12 months

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Tumor signatures
Ramy czasowe: Up to 12 months

Mutations identified by whole exome sequencing (WES) will focus on the PI3K/AKT/mTOR pathway and common alterations associated with prostate cancer, lineage plasticity, and therapeutic resistance. Paired baseline and on-treatment tumor samples will be used to assess pharmacodynamic changes in transcriptional programs and AKT pathway signaling. Baseline tumor WES with matched germline deoxyribonucleic acid (DNA) will be used to characterize genomic alterations in the enrolled population.

Up to 12 months
Change in variant allele frequencies of tumor mutations in circulating tumor DNA (ctDNA)
Ramy czasowe: At cycle 3 (cycle length = 28 days)

Will be compared to pretreatment. Serial ctDNA dynamics will be explored for association with metabolic response, radiographic response/progression, and clinical outcomes. Given the sample size, correlative analyses will be hypothesis-generating.

At cycle 3 (cycle length = 28 days)
Change in FDG uptake (SUVtotal) in prostate-specific membrane antigen (PSMA)-positive and PSMA-negative lesions
Ramy czasowe: Up to 12 months

Exploratory imaging analyses will evaluate metabolic response globally and, when feasible, by lesion phenotype, including PSMA-positive and PSMA-negative lesions. Lesion-level analyses will be descriptive and exploratory, with attention to within-patient heterogeneity.

Up to 12 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Adel Mandl, JHU Sidney Kimmel Comprehensive Cancer Center LAO

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

26 lutego 2027

Zakończenie podstawowe (Szacowany)

4 stycznia 2029

Ukończenie studiów (Szacowany)

4 stycznia 2029

Daty rejestracji na studia

Pierwszy przesłany

31 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

31 października 2026

Pierwszy wysłany (Rzeczywisty)

4 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

31 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj